Financial Performance - The company reported a significant loss due to high production costs from its newly established subsidiary, Hanrui Pharmaceutical, which is still in the adjustment phase, leading to lower product yield [4]. - Asset impairment losses and credit impairment losses increased compared to the same period in 2021, impacting overall financial performance [4]. - The company recognized goodwill impairment of approximately 14 million yuan, reflecting the operational challenges faced by its subsidiaries [4]. - The company's operating revenue for 2022 was ¥688,625,991.71, representing a 12.03% increase compared to ¥614,683,452.35 in 2021 [23]. - The net profit attributable to shareholders for 2022 was a loss of ¥14,029,613.72, a decrease of 150.73% from a profit of ¥27,654,228.04 in 2021 [23]. - The cash flow from operating activities for 2022 was ¥53,033,664.59, a significant increase of 338.72% compared to ¥12,088,247.37 in 2021 [23]. - The basic and diluted earnings per share for 2022 were both -¥0.11, down 142.31% from ¥0.26 in 2021 [23]. - The total assets at the end of 2022 were ¥2,706,360,990.39, a slight increase of 0.33% from ¥2,697,511,886.43 at the end of 2021 [23]. - The net assets attributable to shareholders at the end of 2022 were ¥2,310,371,030.54, a decrease of 0.60% from ¥2,324,400,644.26 at the end of 2021 [23]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a loss of ¥47,851,814.16 in 2022 compared to a profit of ¥5,591,250.83 in 2021, a decrease of 955.83% [23]. Business Operations - The company's core business remains stable, focusing on the production and sales of large molecule biopharmaceuticals, small molecule chemical drugs, and APIs, with no significant adverse changes in its fundamentals [6]. - The company is actively involved in CRO, CMO, and CDMO services, providing contract research and manufacturing services to domestic and international pharmaceutical companies [6]. - The company is in the process of establishing a high-end API production base, which is expected to enhance its operational capacity in the future [4]. - The company operates in the pharmaceutical manufacturing sector, focusing on the production and sales of large molecule biological drugs and small molecule chemical drugs [33]. - The company aims to create innovative drugs, with its leading product being the Class I new drug, Jinlujie, an injectable nerve growth factor [34]. - The company has a subsidiary, Xiamen Weijia, which specializes in the research and production of antiviral drugs, including nucleoside and protease inhibitors [34]. - The company is focused on the development, production, and sales of innovative biopharmaceuticals, including injectable mouse nerve growth factor and antiviral drugs [44]. - The company has established six high-end formulation R&D platforms to enhance drug project success rates [42]. - The company provides a full range of drug development services, including small molecule drug R&D and contract manufacturing [39][43]. Market Trends - The global biopharmaceutical market grew from $239.6 billion in 2017 to $338.4 billion in 2021, with a CAGR of 9.0% [35]. - The Chinese biopharmaceutical market expanded from ¥218.5 billion in 2017 to ¥410 billion in 2021, achieving a CAGR of 17.0% [36]. - The market size of the Chinese biopharmaceutical industry is expected to reach ¥1,199.1 billion by 2030, with a CAGR of approximately 12.7% from 2021 to 2030 [36]. - The market for injectable mouse nerve growth factor peaked at ¥3.3 billion in 2016 but has since declined due to policy changes, with a gradual stabilization expected in the coming years [37][38]. - The global CRO market increased from $49 billion in 2017 to $71 billion in 2021, with a CAGR of 9.7% [40]. - The Chinese CRO market grew from ¥29 billion in 2017 to ¥63.9 billion in 2021, with a CAGR of 21.8% [41]. Research and Development - The company has established a clinical trial institution data archive, gathering information on institution names, specialties, researchers, and research experience to ensure smooth clinical research operations [54]. - The company has a dedicated technical center with strong capabilities in new product research and development, focusing on projects like recombinant human nerve growth factor and thymopentin [57]. - The company has been approved as a national postdoctoral research station, collaborating with institutions like Huazhong University of Science and Technology to enhance new drug innovation projects [57]. - The company is developing multiple small molecule chemical generic drugs and active pharmaceutical ingredients, with progress reported as smooth [69]. - The company is developing multiple new products, including a recombinant human nerve growth factor eye drop and various generic injectable drugs, which are expected to enhance the product pipeline and revenue [90]. Financial Management - The company plans not to distribute cash dividends or issue bonus shares, indicating a focus on reinvestment [7]. - The company has established a dedicated bank account for the management of raised funds, ensuring proper tracking and usage of the funds [106]. - The total amount of committed investment projects is CNY 22,000 million, with a cumulative investment of CNY 4,925.86 million, achieving 100.00% of the planned investment [107]. - The company has effectively utilized the raised funds, with a total investment of CNY 1,782.44 million in the laboratory construction project [107]. - The company has not reported any issues or discrepancies in the use of raised funds, which are currently held in dedicated accounts and low-risk financial products [111]. Governance and Compliance - The company has established specialized committees within the board to enhance governance and oversight functions [146]. - The supervisory board comprises 3 members, including a representative from employees, ensuring compliance and protection of shareholder rights [147]. - The company operates independently from its controlling shareholder in terms of business, assets, personnel, institutions, and finance, ensuring a complete and autonomous business system [150]. - The company has established an independent R&D, procurement, and sales system, demonstrating its capability to conduct production and operational activities autonomously [153]. - The company emphasizes transparency in information disclosure, adhering to relevant laws and regulations to ensure all shareholders receive accurate information [152]. Environmental Responsibility - The company has obtained necessary environmental permits, including a pollution discharge permit valid until September 21, 2023 [197]. - The company adheres to various environmental protection laws and standards relevant to its operations [196]. - The company is committed to sustainable practices and continuous improvement in its environmental performance [198]. - The wastewater treatment processes are designed to minimize environmental impact while maintaining operational efficiency [200]. - The company is actively monitoring and managing its emissions to meet environmental standards and regulations [198].

武汉海特生物制药股份有限公司 2023 年第一季度报告 证券代码：300683 证券简称：海特生物 公告编号：2023-026 武汉海特生物制药股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经过审计 □是 否 1 武汉海特生物制药股份有限公司 2023 年第一季度报告 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 口是 ☑否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | (%) | | | 营业收入(元) | 138.635.351.99 | 166. 204. 766. 30 ...

武汉海特生物制药股份有限公司（以下简称"公司"）决定于 2023 年 5 月 8 日 15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度业绩说明会将采用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 陆 全 景 网 " 投 资 者 关 系 互 动 平 台 " （https://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总经理陈亚先生、副总经理兼董事 会秘书陈煌先生、财务总监夏汉珍女士、独立董事冉明东先生和保荐代表人孙素 淑女士将出席本次业绩说明会。 为更好地回复投资者关注的问题，使投资者更加充分地了解公司生产经营、 发展战略情况以及所处行业的动态变化等，切实保护好广大投资者，尤其是中小 投资者的利益，提升本次业绩说明会的交流效果及针对性，现就公司 2022 年度 业绩说明会提前向投资者征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 8 日 15:00 前访问 http://ir.p5w.net/zj/或扫描下方二维码，进入问题征 集专题页面进行提问。 敬请广大投资者通过全景网系统提交您所关注的问题，便于公司在 ...

证券代码： 300683 证券简称：海特生物 武汉海特生物制药股份有限公司投资者关系活动记录表 编号：2020-01 | --- | --- | --- | |----------------|------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □√ 其他 （电话交流会） | | | 参与单位名称及 | | 煜德投资冯超，上海乾瞻施卫平，多和美刘庆，高特佳投资 | | 人员姓名 | 李彦格， | 刘泽序，涂洋，进化论资产李艳杰，四川诚卓投资 | | | | 袁婷婷，上海厚磊投资管理有限公司张亚北，湖北正知投资 | | | | 有限公司孙浩，博时基金尹哲，中信证券陈竹、郑洁君，景 | | | | 泰利丰邹军辉，壹玖资产郑森峰，智飞生物田加强，东方基 | | | 金欧阳娟。 | | | --- | - ...

证券代码： 300683 证券简称：海特生物 武汉海特生物制药股份有限公司投资者关系活动记录表 编号：2017-01 | --- | --- | --- | |-------------------|-------------------------|------------------------------------------------------| | | | | | 投 资 者 关 系 活 | √ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | √ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 | | 上海证券报 雷中校、陈捷、王宏斌、覃秘 | | 及人员姓名 | | 长江证券 高颖岚、陈隽、尹章程、罗方文、罗聪、高峻霄 | | | 芦彦岭 | | | 时间 | 2017 年 11 月 2 | 日 | | 地点 | | 武汉经济技术开发区海特科技园海特生物会议室 | | 上 市 公 司 接 待 | | 董事长兼总经理陈亚先生、副总经理兼董秘陈煌先生、财务 ...

编号：2022-01 证券代码： 300683 证券简称：海特生物 | --- | --- | --- | --- | |----------|----------------|----------------------------------|------------------------------------| | | | | | | | 投资者关系活动 | □特定对象调研 □分析师会议 | | | 类别 | | □媒体采访 □业绩说明会 | | | | | □新闻发布会 | □路演活动 | | | | | | | | | （电话交流会） | | | | 参与单位名称及 | 周新明、于彦秋 民生加银 | 郝梦娇 | | 人员姓名 | | 蔡强 工银瑞信 | 丁洋、李善欣 | | | | 易小金 纯达基金 | 周纯 | | | | 张秀磊 泰康资产 | 涂健 | | | | 西部利得基金 | 冯皓琪 海富通基金 高强 | | | | 吴县名 | | | 时间 | | 月 6 日 | | | 地点 | | | | | | 上市公司接待人 | 董事会秘书陈煌先生 | | | 员姓名 | | | | | 投 ...

武汉海特生物制药股份有限公司 武汉海特生物制药股份有限公司 2022 年第三季度报告 证券代码：300683 证券简称：海特生物 公告编号：2022-056 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 武汉海特生物制药股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 （二） 非经常性损益项目和金额 适用 □不适用 | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | --- | | 非流动资产处置损益（包括 | | | | | 已计提资产减值准备的冲销 | 347,191.32 | 252,478.69 | | | 部分 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 387,232,225.48, representing a 71.69% increase compared to CNY 225,544,650.45 in the same period last year[22]. - The net profit attributable to shareholders was CNY 18,872,041.54, a significant increase of 161.49% from CNY 7,217,211.13 year-on-year[22]. - The net profit after deducting non-recurring gains and losses was CNY 8,138,113.45, up 145.50% from CNY 3,314,935.21 in the previous year[22]. - The basic earnings per share rose to CNY 0.15, an increase of 114.29% compared to CNY 0.07 in the same period last year[22]. - The total assets at the end of the reporting period were CNY 2,694,739,543.56, a slight decrease of 0.10% from CNY 2,697,511,886.43 at the end of the previous year[22]. - The net assets attributable to shareholders increased by 0.81% to CNY 2,343,272,685.80 from CNY 2,324,400,644.26 at the end of the previous year[22]. - The net cash flow from operating activities was negative at CNY -28,468,023.50, worsening by 228.35% compared to CNY -8,669,965.73 in the same period last year[22]. - The company reported a total non-operating income of 10,733,928.09, after accounting for tax effects and minority interests[27]. - The company received government subsidies amounting to 3,971,323.59, which are closely related to its normal business operations[26]. - The company reported a loss of 94,712.63 from the disposal of non-current assets, indicating challenges in asset management[26]. Research and Development - The company is actively involved in the research and development of innovative biopharmaceuticals, including a new drug for treating blood system tumors, which has completed Phase III clinical trials[31]. - The company has a leading product, Jinlujie (injection mouse nerve growth factor), which is the world's first commercialized nerve growth factor new drug, launched in 2003[34]. - The company’s innovative products include peptide immune modulators, which enhance the immune response against hepatitis B virus[37]. - The company’s core technology in 3CL protease inhibitors has entered the upstream supply chain for antiviral drugs, showcasing its R&D capabilities[38]. - The company is actively developing multiple small molecule generic drugs and raw materials, with significant progress reported in various projects, including the submission of new drug applications for several products[47]. - The company aims to increase the proportion of self-developed products through its own production capabilities[45]. - The company has established a strong R&D platform and is enhancing its independent R&D system, with a focus on optimizing talent structure and expanding research areas[49]. - The company has developed over 400 products, with 165 clinical approvals and 43 production approvals, including 26 new drug certificates, demonstrating its strong product pipeline[52]. - The company is in the NDA stage for its CPT project, a Class I anti-tumor new drug, indicating significant progress in its innovative drug development[52]. Market Strategy and Operations - The company plans to diversify its product offerings in the next three years, focusing on innovative biopharmaceuticals, small molecule CRO, CDMO, and high-end raw materials[47]. - The company’s subsidiary, Tianjin Hankan, provides comprehensive CRO services, including drug research and clinical trials, enhancing the value chain in pharmaceutical development[39]. - The company’s subsidiary, Xiamen Weijia, specializes in antiviral drug production and has become a key supplier of APIs and intermediates in the domestic and international markets[38]. - The company maintains strong channel advantages in neurology and oncology, supported by a nationwide sales service network and partnerships with major pharmaceutical distributors[53]. - The company is expanding its market presence by actively seeking overseas clients for its CRO and CDMO services, contributing to rapid business growth[47]. - The company emphasizes maintaining strong communication with regulatory experts to facilitate successful product registration[40]. - The company is focusing on enhancing its production capabilities through the establishment of a new manufacturing center for small-volume injectables and solid oral formulations[80]. - The company aims to improve operational efficiency and reduce reliance on single products through strategic acquisitions and investments in R&D[80]. Financial Management and Investments - The company reported a total of ¥519,399,287.66 in financial assets, with a fair value change of ¥1,800,064[68]. - The company has raised a total of 63,693.7 million CNY for various projects, with 41,612.1 million CNY actually invested, representing an investment progress of approximately 65.2%[80]. - The company has committed 6,590 million CNY to bank wealth management products and 18,000 million CNY to broker wealth management products, with no overdue amounts reported[82]. - The company has a total of 38,730 million CNY in entrusted wealth management, with all funds currently performing as expected[82]. - The company reported a net increase in cash and cash equivalents of ¥307,837,329.01, a 217.69% improvement compared to the previous year[57]. - The company reported a significant reduction in credit impairment losses, which were CNY -1,363,965.07 compared to CNY -11,447,012.70 in the first half of 2021[1]. - The company reported a net cash flow from investment activities of 342,258,067.83 CNY for the first half of 2022, a substantial improvement from -249,844,406.39 CNY in the same period of the previous year[178]. - The company reported a loan interest income of approximately CNY 2.97 million from Beijing Shadong Biotechnology Co., Ltd. during the first half of 2022[127]. Corporate Governance and Compliance - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and regulations, and protecting the rights of all shareholders, especially minority shareholders[112]. - The company has implemented a comprehensive information disclosure management system to ensure timely and accurate communication with shareholders[113]. - The company has established a workers' representative assembly and union to safeguard employee rights and facilitate communication between employees and management[114]. - The company has not reported any significant litigation or arbitration matters during the reporting period, indicating a stable legal environment[124]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period, reflecting sound financial practices[120]. - The company has not engaged in any major related party transactions during the reporting period, maintaining transparency in its operations[125]. - The company has not encountered significant changes in the feasibility of its projects[76]. - The company has not undergone any bankruptcy restructuring or related matters during the reporting period, suggesting financial stability[123]. Environmental Responsibility - The company has a wastewater treatment capacity of 500 tons per day, with all wastewater treated to meet discharge standards[106]. - The company has implemented a self-monitoring plan for emissions, which has been approved by the environmental protection authority[109]. - There were no administrative penalties due to environmental issues during the reporting period[110]. - The company has established an emergency response plan for environmental incidents, which has been filed with the environmental protection department[108]. - The company emphasizes its commitment to social responsibility, engaging in charitable activities to support patients with neurological disorders and collaborating with environmental NGOs for sustainable development[116]. Shareholder Information - The largest shareholder, Wuhan Sanjiangyuan Investment Development Co., Ltd., holds 32.76% of the shares, totaling 40,000,000 shares[148]. - The second-largest shareholder, Chen Ya, holds 9.05% of the shares, totaling 11,050,000 shares, with 8,600,000 shares under lock-up[148]. - The company has a total of 12,689 shareholders at the end of the reporting period[148]. - The total number of unrestricted shares increased from 95,057,790 to 112,556,915, with an increase of 17,499,125 shares, representing 92.18% of the total[143]. - The company reported a total of 122,104,165 shares, with no changes in the number of shares during the reporting period[144]. - The report indicates that there were no new shares issued or repurchased during the period[146].

武汉海特生物制药股份有限公司 2022 年半年度报告全文 武汉海特生物制药股份有限公司 2022 年半年度报告 武汉海特生物制药股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人陈亚、主管会计工作负责人夏汉珍及会计机构负责人(会计主 管人员)羡雯声明：保证本半年度报告中财务报告的真实、准确、完整。 2022-037 所有董事均已出席了审议本报告的董事会会议。 2022 年 8 月 公司在生产经营中可能存在产业政策风险、CPT 的新药注册与市场风险、 新药研发风险、募投项目实施风险等风险，有关风险因素具体内容在本报告 第三节"管理层讨论与分析"之十"公司面临的风险和应对措施"章节中对 面临的风险予以描述，敬请投资者注意投资风险。 1 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第二节 | 公司简介和主要财务指标 7 | | | --- | --- | --- | | 第三节 | 管理层讨论与分析 ...

证券代码：300683 证券简称：海特生物 公告编号：2022-027 武汉海特生物制药股份有限公司 关于参加2022年湖北辖区上市公司投资者 集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、召开时间：2022年6月16日（星期四）13:00-16:00 2、召开方式：网络在线交流方式 一、活动安排 为进一步加强武汉海特生物制药股份有限公司（以下简称"公司"）与投资 者互动交流，便于广大投资者更深入全面地了解公司情况，公司决定于2022年6 月16日13:00-16:00以网络在线交流方式参加湖北证监局、湖北省上市公司协会、 深圳市全景网络有限公司联合举办的"2022年湖北辖区上市公司投资者集体接待 日暨2021年度业绩说明会活动"。公司将积极参与活动，并围绕2021年度业绩、 公司治理、经营状况、可持续发展情况等投资者所关心的问题，通过互动平台与 投资者进行沟通交流。 二、活动的时间、方式 活动时间：2022 年 6 月 16 日（星期四）13：00-16：00 活动方式：网络远程形式，通过"全景路演"网站（http ...